stk33

STK33-IN-1 (compound 1) is a potent STK33 inhibitor with an IC50 of 7 nM.

ML281, a potent and selective STK33 inhibitor, exhibits an IC50 of 14 nM.

Mps1-IN-2 is a potent, selective, and ATP-competitive inhibitor of both Mps1 and Plk1.

CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.

MPI-0479605 is an ATP competitive and selective inhibitor.

CDD-2210 is an STK33 inhibitor with a Kd value of 0.1 nM and an IC50 value of 38 nM. Its inhibitory effects on off-target kinases are relatively weak, with IC50 values for CLK1, CLK2, CLK4, and RET being 1209 nM, 917 nM, 544 nM, and 746 nM, respectively. CDD-2210 is applicable for contraceptive research.

CDD-2211 is an STK33 inhibitor with a Kd value of 0.018 nM and an IC50 value of 5 nM. It exhibits weak inhibition of off-target kinases, with IC50 values of 115 nM, 48 nM, 187 nM, and 78 nM for CLK1, CLK2, CLK4, and RET, respectively. CDD-2211 may be used in contraception research.

CDD-2212 is an STK33 inhibitor with a Kd of 1.9 nM and an IC50 of 999 nM. It exhibits weak inhibitory activity against off-target kinases, with IC50 values of 3223 nM for CLK1, 1555 nM for CLK2, 5884 nM for CLK4, and 1093 nM for RET. CDD-2212 is applicable in contraceptive research.

BRD-8899 is an STK33 inhibitor with an IC₅₀ of 11 nM [1].